Compare GRC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRC | CSTL |
|---|---|---|
| Founded | 1933 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2019 |
| Metric | GRC | CSTL |
|---|---|---|
| Price | $48.05 | $38.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $42.83 |
| AVG Volume (30 Days) | 87.5K | ★ 363.9K |
| Earning Date | 02-06-2026 | 11-03-2025 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ 31.51 | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $678,522,000.00 | $343,530,000.00 |
| Revenue This Year | $4.94 | $1.69 |
| Revenue Next Year | $4.02 | N/A |
| P/E Ratio | $24.97 | ★ N/A |
| Revenue Growth | 3.19 | ★ 10.15 |
| 52 Week Low | $30.87 | $14.59 |
| 52 Week High | $52.02 | $42.18 |
| Indicator | GRC | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 54.00 |
| Support Level | $48.11 | $38.75 |
| Resistance Level | $50.58 | $39.76 |
| Average True Range (ATR) | 1.09 | 1.18 |
| MACD | -0.25 | -0.44 |
| Stochastic Oscillator | 15.83 | 19.71 |
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.